Darwin Global Management, Ltd. Vaxcyte, Inc. Transaction History

Darwin Global Management, Ltd.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$70.52 - $117.12 $8.27 Million - $13.7 Million	117,241 Added 5.63%	2,198,187 $251 Million
Q2 2024 Aug 14, 2024	SELL	$60.06 - $78.77 $40.2 Million - $52.8 Million	-669,858 Reduced 24.35%	2,080,946 $157 Million
Q1 2024 May 15, 2024	BUY	$59.79 - $81.05 $130 Million - $176 Million	2,170,845 Added 374.31%	2,750,804 $188 Million
Q4 2023 Feb 14, 2024	BUY	$45.35 - $63.41 $26.3 Million - $36.8 Million	579,959 New	579,959 $36.4 Million

349

130M

539K

253K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $4.73B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Darwin Global Management, Ltd., based on Form 13F filings with the SEC.

Stay updated on Darwin Global Management, Ltd. with notifications on news.